The effect of shiga toxin on weibel-palade bodies in primary human endothelial cells

about

The effect of shiga toxin on weibel-palade bodies in primary human endothelial cells

Item

http://www.wikidata.org/entity/Q41872877

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

The effect of shiga toxin on weibel-palade bodies in primary human endothelial cells

@en

type

Item

label

The effect of shiga toxin on weibel-palade bodies in primary human endothelial cells

@en

prefLabel

The effect of shiga toxin on weibel-palade bodies in primary human endothelial cells

@en

P1476

The effect of shiga toxin on weibel-palade bodies in primary human endothelial cells

@en

P2093

Joyce Geelen

http://www.w3.org/2001/XMLSchema#string

Koen Mertens

http://www.w3.org/2001/XMLSchema#string

Leo Monnens

http://www.w3.org/2001/XMLSchema#string

Maartje van den Biggelaar

http://www.w3.org/2001/XMLSchema#string

Peter Linssen

http://www.w3.org/2001/XMLSchema#string

Thea van der Velden

http://www.w3.org/2001/XMLSchema#string

P2860

Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers

von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.

Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.

Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Treatment of typical (enteropathic) hemolytic uremic syndrome.

Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome.

An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values.

A novel strategy for hemolytic uremic syndrome: successful treatment with thrombomodulin α.

Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy.

Possible C1q bypass loop activation in the haemolytic uraemic syndrome.

P304

101-107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000363299

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265299601

http://www.w3.org/2001/XMLSchema#string

P698

25177338

http://www.w3.org/2001/XMLSchema#string

P932

4130816

http://www.w3.org/2001/XMLSchema#string